Baotou Dongbao Bio-Tech Co., Ltd.
包头东宝生物技术股份有限公司成立于 1997 年，是中国专业的明胶和水解胶原蛋白制造商，2011年7月6日在深圳证券交易所上市（东宝生物，300239）。公司结合自主创新与科研，在明胶和胶原蛋白肽行业具竞争力。
简介
Baotou Dongbao Bio-Tech Co., Ltd. (创业板300239, 深交所) is a gelatin/collagen and “collagen+” health-wellness materials company, focused on R&D, production and sales of gelatin and collagen derivatives. Core products include gelatin (including “药典二部/代血浆明胶”), collagen peptides/collagen protein (e.g., “圆素”品牌胶原蛋白/胶原肽), empty capsules (e.g., “箭牌”空心胶囊; also enteric-coated/other capsule types via 控股子公司益青生物) plus “胶原+”终端营养健康品 (保健食品/营养与美妆个护等). Founded 1997-03-12; HQ/office address: 内蒙古自治区包头市稀土高新技术产业开发区黄河大街46号. It is publicly listed;实际控制人为王爱国、徐波；大股东信息在企查到/年报摘要中提及国恩科技等（具体持股比例见相关股东条目）. Scale (where known): employees about 1,385–1,424 (reported as 1,424)；2025营业收入约7.45亿元，2025末总资产约25.50亿元；2025年净利润约-?（年报摘要给出归母净利润约5433.73万、下降36.8%）. Technology/quality: production capability明胶年产能13,500吨、胶原蛋白年产能4,300吨；空心胶囊益青生物现有年产约240亿粒，并推进扩产（规划全部投产后近700亿粒）. Certifications/registration include FSSC22000、ISO体系、CNAS检测中心；明胶/胶原肽获得欧盟注册、美国FDA/DMF注册并通过NSF-GMP等. Key partners/customers:年报披露B2B客户群体稳定且与国内空心胶囊与大型医药企业等保持长期合作关系（具体名单未在结果中给出）. Latest 2025-2026 developments: 2026-06-12至06-15有机构调研与信息披露；2026-06-24有投资者教育活动；2026年仍在公告/接待调研，表明持续经营与活跃。关于2025-2026是否仍活跃：是，2026年仍有公告与调研活动. Latest financial/capacity updates are consistent with推进空心胶囊“智能产业化”扩产与提升胶原+应用布局. Sources:.
Sources#
- 行业
- 化妆品
- 主题
- 透明质酸、胶原蛋白与化妆品生物活性成分
- 角色
- 研究机构 — “…dependent R&D with industry-university-research cooperation; long-standing collaboration with the Chinese Acad…”
- 为何属于生物经济
- 包头东宝生物技术股份有限公司是在营上市公司，成立于 1997 年——制造食品/健康和药用胶囊用明胶和胶原蛋白（含水解胶原蛋白/胶原蛋白肽）。
- 发现途径
- Jiangsu Jland Biotech; Jiangsu Trautec
供应的生物解决方案 1
产品与服务
子公司: 青岛益青生物科技股份有限公司 (益青生物) · 内蒙古东宝大田生物科技有限公司 (东宝大田)
新闻与状态 6
- 2026-08 最新状态: 公司继续作为深圳证券交易所上市公司运营，2026年提交了涉及财务报告、债券付息和资本变动的监管文件。 ↗ ↗ ↗
- 2026-08-23 Baotou Dongbao Bio-Tech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2026 | MarketScreenerBaotou Dongbao Bio-Tech Co., Ltd.'s half-year results show stronger sales of 414.69 million CNY, up from 369.06 million last year, with net income of 37.4 million CNY (slightly higher than 36.97 million). Basic EPS from continuing operations is 0.063 CNY and …
- 2026-08-25 财报快递|东宝生物2026年上半年增收不增利，明胶毛利率骤降5.48个百分点 - 投资逻辑解析 - 股百科Baotou Dongbao Biotech (Dongbao Biotech) reported 1H2026 revenue up 12.4% to 414.7 million yuan, but net profit barely grew (up 1.2%), with gross margin down overall, driven by a sharp drop in gelatin margins. The company highlights expanding gelatin revenue …
- 2026-08-10 再添“新军”！自治区级生物制造产业知识产权运营中心落户包头-其他_ 天眼查新闻Baotou Dongbao Bio-Technology Co., Ltd. is highlighted as the latest beneficiary of an autonomous regional IP operation center for the biomanufacturing industry, indicating its prominence in biomanufacturing IP promotion and its leadership within Baotou's …
- 2026-05-27 东宝生物：投资者关系管理信息20260527|查股网Baotou Dongbao Bio-Tech Co., Ltd. held a virtual investor relations meeting on May 27, 2026, updating on expansion plans for its hollow capsule production to be fully operational by March 2027, current sales growth in collagen-related products including its …
- 2026-08-23 东宝生物上半年营收4.15亿元同比增12.37%，归母净利润3740.40万元同比增1.18%，毛利率下降3.36个百分点 - 今日头条Baotou Dongbao Bio-Tech Co., Ltd. reported 2026 H1 revenue of 4.15 billion yuan (up 12.37%) and net profit attributable to shareholders of 37.404 million yuan (up 1.18%), with gross margin of 22.08% (down 3.36pp) and net margin 9.02% (down 1pp); basic earnings …
- 2026-04-13 调研速递|东宝生物(123214)接受投资者线上调研 胶囊项目稳步推进、锂电铜箔添加剂业务重点发力|投资者_新浪财经_新浪网Baotou Dongbao Bio-Tech Co., Ltd. reports progress on its capsule expansion project (completed major civil works and partial equipment installation, with asset-light, optimized capacity structure) and highlights the promising use of its collagen-based additive …
关系网络：股东、合作伙伴、同类
股权与投资方 3
| 母公司 | 王爱国, 徐波 |
| 子公司 | 青岛益青生物科技股份有限公司 |
| 子公司 | 内蒙古东宝大田生物科技有限公司 |
合作与交易 3
| 交易对手 | Qingdao Gon Technology Co …The company continues to operate as a publicly listed entity on the Shenzhen Stock Exchange, with recent regulatory filings in 2026 regarding financial reports, bond interest payments, and capital …… |
| 交易对手 | Ltd. (parent company) …The company continues to operate as a publicly listed entity on the Shenzhen Stock Exchange, with recent regulatory filings in 2026 regarding financial reports, bond interest payments, and capital …… |
| 合作 | Combines independent R&D …ciences, other international partners). Combines independent R&D with industry-university-research cooperation; long-standing collaboration with the Chinese Academy of Sciences’ Institute of Physical… |
同类企业
Nippi, Inc. · Nitta Gelatin India Limited · Shandong Hengxin Biotech Co., Ltd · BLG · LanPu Gelatin · Yasin Gelatin · HALAGEL (M) SDN BHD · Xushang Gelatin Co.Ltd
身份与联系方式
联系方式、人员和法律信息仅向会员开放。
会员登录